BridgeBio logo

Talent Acquisition - BridgeBio

View Company Profile
Job Title
Talent Acquisition
Job Location
Hybrid/San Francisco, CA & Palo Alto, CA
Job Description

BridgeBio is a biopharmaceutical organization dedicated to discovering, creating, testing, and delivering transformative medicines for patients impacted by genetic diseases and cancers. We take pride in bringing together some of the brightest minds to bridge scientific breakthroughs and life-changing therapies, driving growth in a purpose-led environment. 

As we continue expanding our organization and broadening our impact, we’re proactively engaging with experienced Talent Acquisition professionals who are passionate about talent strategy, building high-performing teams, and contributing to meaningful work in biotech.

This prospecting role is designed to engage individuals who are curious about BridgeBio and open to future Talent Acquisition opportunities as our needs expand. If you enjoy partnering with leaders, shaping hiring strategies, and contributing to meaningful growth, please submit your information and we’d love to start a conversation! 

Everything You Need, One Platform.

From job listings to startups, investors to funding rounds, and everything in between, Employbl puts the power in your hands. Why wait?

Start your free trial today!


Stay Ahead of the Curve

Sign up for our newsletter to stay informed about the latest startups and trends in the tech market. Let Employbl be your guide to success.

BridgeBio Headquarters Location

Palo Alto, CA

View on map

BridgeBio Company Size

Between 730 - 730 employees

BridgeBio Founded Year

2014

BridgeBio Total Amount Raised

$4,349,199,360

BridgeBio Funding Rounds

View funding details
  • Post Ipo Debt

    $500,000,000 USD

  • Post Ipo Equity

    $250,000,000 USD

  • Post Ipo Debt

    $1,250,000,000 USD

  • Post Ipo Equity

    $250,000,000 USD

  • Post Ipo Equity

    $150,000,000 USD

  • Post Ipo Debt

    $750,000,000 USD

  • Post Ipo Debt

    $250,000,000 USD

  • Post Ipo Debt

    $475,000,000 USD

  • Series D

    $299,200,000 USD

  • IPO

    $0

  • Series C

    $135,000,000 USD

  • Series B

    $33,100,000 USD

  • Series B

    $6,900,000 USD